Suzhou Fushilai Pharmaceutical Co., Ltd. Class A

Suzhou Fushilai Pharmaceutical Co., Ltd. Class A

SSZSE:301258
22.50
CNY
-0.12
(-0.53%)
-0.53EPS
2.51BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.79
2.5
4.08
4.94
5.68
5.67
6.71
6.93
7.6
6.6
5.32
4.71
4.78
4.23
Basic EPS, GAAP
0.66
0.1
0.8
0.9
1.17
1.41
2.16
2.05
1.75
2.06
1.22
0.18
0.71
-0.53
Free Cash Flow per Basic Share
-0.12
-0.29
-0.19
0.95
1.24
1.3
1.18
1.47
1.73
1.17
0.58
-0.64
-0.88
- -
Dividend per Share
- -
0.06
0.07
0.05
0.76
0.01
0.73
1.46
0.01
0.43
0.58
0.6
0.09
- -
Book Value per Share
2.83
2.93
3.72
4.92
5.34
6.75
8.46
9.06
10.8
20.58
21.22
20.58
20.34
19.71
Tangible Book Value per Share
2.49
2.61
3.4
4.64
5.06
6.4
8.13
8.73
10.48
20.34
20.99
19.9
19.67
19.06
Basic Weighted Avg Shares
60
58
60
65
66
66
67
69
69
86
92
91
91
89
Sales/Revenue/Turnover
167
144
245
322
375
375
452
477
522
568
489
429
433
375
Operating Margin (%)
26.33
3.35
22.41
19.83
26.15
28.12
37.12
35.21
27.74
30.15
19.67
-0.29
-1.87
-10.61
Depreciation Expense
5
18
22
29
30
31
30
34
46
52
57
49
48
- -
Net Income, GAAP
39
6
48
59
77
93
146
141
120
177
112
16
64
-47
Effective Tax Rate (%)
14.59
9.13
14.43
18.82
14.9
13.77
14.39
14.43
13.18
12.42
12.73
9.92
14.1
- -
Profit Margin (%)
23.65
4
19.61
18.23
20.61
24.85
32.2
29.58
23.04
31.2
22.93
3.82
14.86
-12.58
Working Capital
17
-64
-60
58
101
193
256
262
343
1,500
1,537
1,466
1,312
1,243
LT Debt
30
- -
- -
- -
- -
- -
- -
- -
- -
2
2
1
- -
- -
Total Equity
170
176
223
325
352
446
582
623
743
1,887
1,946
1,887
1,865
1,807
Return on Invested Capital (%)
- -
0.77
16.35
16.42
20.97
23.17
29.55
24.86
18.06
13.62
6.08
0.95
3.51
- -
Return on Capital (%)
- -
3.91
18.52
18.64
21.73
22.76
28.36
23.42
17.48
13.4
5.85
0.86
3.43
- -
Return on Common Equity (%)
- -
3.35
24.14
21.46
22.85
23.37
28.36
23.42
17.61
13.49
5.85
0.86
3.43
-2.53

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1
1
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
92
92
92
Market Capitalization
2,911
2,087
2,512

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,445
1,425
1,386
Cash, Cash Equivalents & STI
1,164
1,146
1,121
Accounts Receivable, Net
76
72
74
Inventories
133
142
137
Total Current Liabilities
139
154
143
Payables & Accruals
- -
- -
- -
ST Debt
1
1
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
29.03%
34.44%
-1.18%
Free Cash Flow
-80.67%
-43.46%
37.17%
Net Income, GAAP
32.99%
40.5%
291.89%
Sales/Revenue/Turnover
6.67%
-1.41%
0.76%
Total Cash Common Dividend
1,757.86%
1,645.56%
-84.97%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
96
120
96
117
429
2025
113
111
- -
110
433
2026
93
93
80
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
-0.07
0.16
0.03
0.18
2025
0.26
0.21
- -
-0.1
0.71
2026
-0.03
-0.13
-0.26
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.6
2025
- -
- -
- -
- -
0.09
2026
- -
- -
- -
- -
- -

Company Description

CEO
Xiang Yun Qian
Full Time Employees
540
Sector
Process industries
Industry
Chemicals: specialty
Address
Changshu China
IPO Date
Mar 29, 2022
Website
fuslai.com
Business
Suzhou Fushilai Pharmaceutical Co., Ltd. is a China-based pharmaceutical and nutritional ingredient manufacturing company primarily engaged in the research, development, production, and distribution of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and dietary supplement raw materials. Founded in 2000 and headquartered in Changshu, Jiangsu Province, China, the company operates across key specialized chemical and health sectors, supplying global pharmaceutical manufacturers, dietary supplement brand owners, food and beverage producers, and cosmetics formulators. The company's core product offerings comprise: the Thioctic Acid series, including alpha-lipoic acid, R-alpha-lipoic acid, sodium R-lipoate, tromethamine lipoate, dihydrolipoic acid, and 6,8-dichlorooctanoic acid ethyl ester, which are widely utilized as antioxidants and active components for diabetic peripheral neuropathy therapeutics, nutritional supplements, and skin health products; the Carnitine series, featuring L-carnitine base, L-carnitine tartrate, L-carnitine fumarate, acetyl-L-carnitine hydrochloride, and propionyl-L-carnitine hydrochloride, applied in infant nutrition, sports nutrition, medical foods, and cardiovascular health formulations; phosphatidylserine and other specialty nutritional bio-compounds; and custom pharmaceutical intermediates and fine chemicals for cardiovascular, metabolic, and antiviral indications. In addition, the company provides Contract Development and Manufacturing Organization (CDMO) and custom synthesis services tailored to customer specifications across laboratory, pilot, and commercial scales. Geographically, the company maintains extensive market coverage across domestic China and exports to major international regions, including North America, Europe, Japan, South Korea, India, and Southeast Asia. In recent developments, Suzhou Fushilai Pharmaceutical Co., Ltd. has accelerated its strategic transition into advanced CDMO services and high-barrier chiral pharmaceutical technologies. The company has expanded its modern cGMP-compliant manufacturing facilities, integrating automated synthesis units, continuous flow processing, and micro-reaction systems to scale production efficiency and environmental sustainability. To diversify its portfolio beyond bulk ingredients, the company has increased research and development investment in enzymatic biocatalysis and green chemistry platforms for high-purity chiral drug intermediates. Additionally, the company has strengthened its global regulatory compliance through expanded international drug master file (DMF) registrations and quality certifications, while establishing deepened commercial supply partnerships with international healthcare conglomerates.